The FDA has approved the company's blood clot prevention device for home use.
Israeli non-invasive medical devices company Medical Compression Systems (MCS) reports that it has received approval from the US Food and Drug Administration (FDA) to sell its ActiveCare@Home device, the next generation of its ActiveCare+SFT device.
The share price of MCS is currently up by more than 26% on the Tel Aviv Stock Exchange.
The device is designed to prevent the formation of blood clots following orthopaedic knee and hip replacement surgery. FDA approval will enable the company to sell its new product directly to patients for home use outside of hospitals.
MCS vice chairman and CEO Gerry Feldman said, "We are delighted to receive FDA approval. The device's existing preventative care capabilities allied to its innovative monitoring and communications capabilities allow improvement in treatment results while reducing costs, including of repeat hospital stays, to the health system and hospitals. We are currently examining various possibilities for marketing the device."
Published by Globes [online], Israel business news - www.globes-online.com - on July 17, 2016
© Copyright of Globes Publisher Itonut (1983) Ltd. 2016
biomed